 |
2 Products |  |
0 Diseases | | 2 Products |
|
2 Trials |  |
8 News |  |
- ||| LBT-3627 / Longevity Biotech
Enrollment open: A Two-Part Single and Multiple Ascending Dose Trial of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LBT-3627 in Healthy Participants and in Participants With Parkinson's Disease. (clinicaltrials.gov) - Aug 6, 2024
P1, N=64, Recruiting, Sponsor: Longevity Biotech Australia Pty Ltd (subsidiary)
Not yet recruiting --> Recruiting
- | 5A apoA-I mimetic peptide / Longevity Biotech
Trial completion date, Trial primary completion date: Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Fx-5A in Healthy Volunteers (clinicaltrials.gov) - Jul 17, 2024
P1, N=64, Recruiting, Sponsor: National Heart, Lung, and Blood Institute (NHLBI)
Not yet recruiting --> Recruiting Trial completion date: Jun 2024 --> Jun 2025 | Trial primary completion date: Jun 2024 --> Jun 2025
- | LBT-3627 / Longevity Biotech
New P1 trial: A Two-Part Single and Multiple Ascending Dose Trial of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LBT-3627 in Healthy Participants and in Participants With Parkinson's Disease. (clinicaltrials.gov) - Jun 19, 2024
P1, N=64, Not yet recruiting, Sponsor: Longevity Biotech Australia Pty Ltd (subsidiary)
- ||||||||| LBT-3627 / Longevity Biotech
Biomarker, Trial termination: Parkinson's Disease Inflammatory Biomarker Profiling (clinicaltrials.gov) - Apr 18, 2024
P=N/A, N=99, Terminated, Sponsor: Longevity Biotech
Trial completion date: Jun 2024 --> Jun 2025 | Trial primary completion date: Jun 2024 --> Jun 2025 Unknown status --> Terminated; COVID-19
- | 5A apoA-I mimetic peptide / Longevity Biotech
Trial completion date, Trial primary completion date: Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Fx-5A in Healthy Volunteers (clinicaltrials.gov) - Jul 13, 2023
P1, N=64, Recruiting, Sponsor: National Heart, Lung, and Blood Institute (NHLBI)
Unknown status --> Terminated; COVID-19 Trial completion date: Jun 2023 --> Jun 2024 | Trial primary completion date: Jun 2023 --> Jun 2024
- | 5A apoA-I mimetic peptide / Longevity Biotech
Trial completion date, Trial primary completion date: Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Fx-5A in Healthy Volunteers (clinicaltrials.gov) - Aug 27, 2021
P1, N=64, Recruiting, Sponsor: National Heart, Lung, and Blood Institute (NHLBI)
Trial completion date: Jun 2023 --> Jun 2024 | Trial primary completion date: Jun 2023 --> Jun 2024 Trial completion date: Jun 2022 --> Jun 2023 | Trial primary completion date: Jun 2022 --> Jun 2023
- | 5A apoA-I mimetic peptide / Longevity Biotech
Enrollment open: Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Fx-5A in Healthy Volunteers (clinicaltrials.gov) - Sep 3, 2020
P1, N=64, Recruiting, Sponsor: National Heart, Lung, and Blood Institute (NHLBI)
Trial completion date: Jun 2022 --> Jun 2023 | Trial primary completion date: Jun 2022 --> Jun 2023 Not yet recruiting --> Recruiting
- | 5A apoA-I mimetic peptide / Longevity Biotech
Trial completion date, Trial primary completion date: Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Fx-5A in Healthy Volunteers (clinicaltrials.gov) - Aug 30, 2020
P1, N=64, Not yet recruiting, Sponsor: National Heart, Lung, and Blood Institute (NHLBI)
Not yet recruiting --> Recruiting Trial completion date: Dec 2020 --> Jun 2022 | Trial primary completion date: Dec 2020 --> Jun 2022
- | 5A apoA-I mimetic peptide / Longevity Biotech
New P1 trial: Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Fx-5A in Healthy Volunteers (clinicaltrials.gov) - Jan 2, 2020
P1, N=64, Not yet recruiting, Sponsor: National Heart, Lung, and Blood Institute (NHLBI)
- | LBT-3627 / Longevity Biotech
Journal: A Synthetic Agonist to Vasoactive Intestinal Peptide Receptor-2 Induces Regulatory T Cell Neuroprotective Activities in Models of Parkinson's Disease. (Pubmed Central) - Oct 18, 2019
Herein, a vasoactive intestinal peptide receptor-2 (VIPR2) peptide agonist, LBT-3627, was developed as a neuroprotectant for PD-associated dopaminergic neurodegeneration...Taken together, these data provide the basis for the use of VIPR2 agonists as potent therapeutic immune modulating agents to restore Treg activity, attenuate neuroinflammation, and interdict dopaminergic neurodegeneration in PD. The data underscore an important role of immunity in PD pathogenesis.
- || LBT-3627 / Longevity Biotech
Biomarker, Enrollment status: Parkinson's Disease Inflammatory Biomarker Profiling (clinicaltrials.gov) - May 22, 2019
P=N/A, N=134, Recruiting, Sponsor: Longevity Biotech
The data underscore an important role of immunity in PD pathogenesis. Enrolling by invitation --> Recruiting